Free Trial Information
BioCentury | Jul 15, 2020
Product Development

INmune therapy shows promise in Alzheimer’s, but cognitive test still to come

After reporting its TNF inhibitor reduced brain inflammation in Alzheimer’s disease patients, INmune will need to show that reducing inflammation translates into a cognitive benefit in a Phase II trial planned for next year. The...
Read More
BioCentury | Jun 20, 2020
Translation in Brief

CAR Ts against senescent cells; plus NIH program for ALS, sex-dependent COVID-19 immune responses and more

...disease outcomes. In female patients, those with high levels of the innate immune cytokines IL-15, RANTES...
...Targets IL-15 - Interleukin-15 PLAUR (uPAR) (suPAR) - Plasminogen activator urokinase receptor RANTES (CCL5) - Chemokine CC motif ligand 5...
...Amsterdam BridgeBio Pharma Inc. Johns Hopkins University Plasminogen activator urokinase receptor (PLAUR) (uPAR) (suPAR) SARS-CoV-2 spike protein (SARS-CoV-2 S) Interleukin-15 (IL-15) Chemokine CC motif ligand 5 (RANTES) (CCL5) Tumor...
Read More
BioCentury | Apr 15, 2020
Product Development

AZ targeting cytokine storms as ranks of repurposed agents for COVID-19 grow

AstraZeneca joins the growing list of companies targeting cytokine storms caused by COVID-19 with plans to start a trial of its Btk inhibitor to treat patients with severe disease. The announcement came Tuesday amid another...
Read More
BioCentury | Dec 6, 2019
Targets & Mechanisms

A view of immune reprogramming from ASH

ASH presentations on immune reprogramming point to new targets and mechanisms that control macrophage and T cell phenotype switching, and highlight the phenomenon's translational relevance in diseases beyond solid tumors. Strategies to convert immunosuppressive macrophage...
Read More
BioCentury | Nov 14, 2019
Company News

Nov. 13 Company Quick Takes: FDA panel rebuffs Jardiance; plus Nucala, Cellular Biomedicine, BeiGene, Autolus and Noile-Immune

Panel rebuffs Jardiance for Type I diabetes FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 14-2 Wednesday that available data do not support approval of Jardiance empagliflozin from Boehringer Ingelheim GmbH. The panel was asked...
Read More
BioCentury | Oct 8, 2019

Novel targets induce cardiomyocyte regeneration

DISEASE CATEGORY: Cardiovascular INDICATION: Myocardial infarction (MI) Gene therapies delivering CCL24 or IGF2BP3 could restore cardiac function following MI. RNA-seq analysis identified 874 genes including CCL24 and IGF2BP3 that were upregulated in mouse heart tissue...
Read More
BioCentury | Oct 3, 2019
Targets & Mechanisms

Stimulating heart regeneration following injury

A multi-omic study of regenerating neonatal hearts has uncovered novel therapeutic targets for cardiac injury post myocardial infarction. Study leader Eric Olson said the findings serve as a resource for understanding the DNA sequences and...
Read More
BioCentury | Aug 27, 2019
Company News

Aug. 27 Company Quick Takes: GSK licenses Ionis HBV program; plus Adaptimmune-Noile, Purdue, Presage-BMS, Kyowa, Alexion, Viela, Kintai, OncoNano

GSK opts into Ionis' HBV program Positive Phase II data prompted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to exercise its option to license exclusive, worldwide rights to an antisense chronic HBV program from Ionis Pharmaceuticals Inc. (NASDAQ:IONS)....
Read More
BioCentury | Aug 21, 2019
Financial News

Oncorus raises $79.5M series B with eye on global development

Nearly half a dozen Korean investment groups joined Oncorus' $79.5 million series B round as part of the company's long-range plan to take its oncolytic virus technology global. Cowen Healthcare Investments and Perceptive Advisors led...
Read More
BioCentury | Jul 2, 2019
Preclinical News

July 2 Preclinical Quick Takes: Semma plans 2020 clinical trials of stem cell-derived islet products and more

...a Science Translational Medicine paper that in a mouse model of MS, the company's OB-002 (5P12-RANTES...
Read More
Items per page:
1 - 10 of 203